Avenue TherapeuticsATXI
13F holders, Q4 2024 (December 31)7holders −1
2new positions
4sold out
$2.00avg. 13F price*
At the end of Q4 2024, 7 institutions reported holding Avenue Therapeutics Inc. (ATXI) in their 13F filings, down 1 from Q3 2024. 2 opened new positions and 4 sold out. The largest holders were Ikarian Capital, LLC ($280K), Boothbay Fund Management, LLC ($82K) and UBS Group AG ($16K).
- Company
- Avenue Therapeutics Inc.
- CUSIP
- 05360L403
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $362K |
| Exits | 4 | $471K |
All 13F filers, Q3 2024 → Q4 2024: 184,226 shares bought and 189,122 shares sold, net −4,896 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Ikarian Capital, LLC | 0.08% | New | 140,000 | $280K |
| Boothbay Fund Management, LLC | 0.00% | New | 41,089 | $82K |
| UBS Group AG | 0.00% | Add +28.9% | 7,920 | $16K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +77.9% | 3,096 | $6K |
| Wells Fargo & Company | 0.00% | Reduce -10.9% | 500 | $1K |
| Bank of America Corp. | 0.00% | Add +40.0% | 14 | $28 |
| SBI Securities Co., Ltd. | 0.00% | — | 9 | $18 |
"% of holder's portfolio" is ATXI's weight in each manager's 13F, not the share of Avenue Therapeutics Inc. the manager owns.